Cdc2 tyr15

Manufactured by Cell Signaling Technology

Sourced in United States

Cdc2 Tyr15 is a lab equipment product that measures the phosphorylation of Cdc2 on Tyr15. Cdc2 is a key cell cycle regulator, and phosphorylation of Tyr15 is an important regulatory mechanism for its activity.

Automatically generated - may contain errors

Lab products found in correlation

4 protocols using cdc2 tyr15

Examining Targeted Cancer Therapy Mechanisms

Check if the same lab product or an alternative is used in the 5 most similar protocols

Ribociclib (S7440) and Infigratinib (S2183) were purchased from Selleck Chemicals and were dissolved in 21% Captisol and 30% PEG300 solution (vehicle) for oral administration. Antibodies against FGFR1 (#9740), FGFR3 (#4574), FGFR4 (#8562), AKT (#9272), Rb (#9313), cyclin B1 (#4138), Cdc25C (#4688), Cyclin D1 (#2978), Cyclin E2 (#4132), survivin (#2803), Sox9 (#82630), cleaved PARP (#5625), β catenin (#8480), α‐tubulin (#2144) and phosphorylation‐specific antibodies against AKT Ser473 (#9271), FRS2‐α Tyr439 (#3861), Rb Ser807/811 (#9308), Histone 3 Ser10 (#9701), Cdc2 Tyr15 (#9111) and Erk1/2 Thr202/Tyr204 (#4370) were obtained from Cell Signaling Technology. Antibodies against CYP3A4 (ab124921) and HNF4‐α (ab201460) were from Abcam. The antibodies against FGFR2 (#sc‐122), Erk1/2 (#sc‐94), FRS2‐α (#sc‐17841), GAPDH (sc‐166545) and Cdk2 Thr14/Tyr15 (#sc‐28435‐R) were from Santa Cruz Biotechnology Inc. Anti‐mouse CD31 antibody (#2502) was from BioLegend. Anti‐albumin (#SAB4200711; clone HAS‐11) antibody was purchased from Sigma‐Aldrich.

Prawira A., Le T.B., Vu T.C, & Huynh H. (2020). Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma. Liver International, 41(3), 608-620.

+ Open protocol

+ Expand

Antibody Detection of Cell Signaling Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols

The antibodies to detect PKM1 (Cat# 7076S), total PKM2 (Cat# 4053S), -CDC2 (Cat# 28439S), p65 (Cat# 8242), cyclin B1 (Cat# 4135S), phosphorylated PKM2 (Tyr; Cat# 3827), CDC2 (Tyr15; Cat# 4539S), and p65 (Ser536; Cat# 3033) were purchased from Cell Signaling Technology (USA). The antibody to detect β-actin (Cat# KM9001) was from Tianjin Sungene Biotech (China). 2-Deoxy-D-glucose (2-DG; Cat# HY-13966) was purchased from MedChem Express (USA).

Ma C., Zu X., Liu K., Bode A.M., Dong Z., Liu Z, & Kim D.J. (2019). Knockdown of Pyruvate Kinase M Inhibits Cell Growth and Migration by Reducing NF-κB Activity in Triple-Negative Breast Cancer Cells. Molecules and Cells, 42(9), 628-636.

+ Open protocol

+ Expand

Vinorelbine and Everolimus Combination Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

Vinorelbine (Navelbine^®) (10 mg/mL) was obtained from Pierre Fabre Medicament (Boulogne, France) and was dissolved in PBS to a final concentration of 0.375 mg/mL before use. Everolimus (RAD001) was obtained from Novartis (Basel, Switzerland) and dissolved in a vehicle (30% Captisol^® in water) to achieve the appropriate concentration for the treatments.
Antibodies against AKT (#9272), p70S6K (#9202), survivin (#2803), S6R (#2217), Rb (#9313), Cyclin B1 (#4138), eIF4E (#9742), Cdc25C (#4688), cleaved caspase 3 (#9661), cleaved caspase 7 (#9491), cleaved PARP (#5625), Cyclin D1 (#2978), Cdc2 (#9112), and α-Tubulin (#2144) and phosphorylation-specific antibodies against RB Ser807/811 (#9308), AKT Ser473 (#9271), mTOR Ser2448 (#5536), p70S6K Thr421/424 (#9204), S6R Ser235/236 (#4858), 4EBP1 Thr70 (#9455), Histone H3 Ser10 (#9701), Cyclin D1 Thr286 (#3300), Cdc25C Ser216 (#4901), Cdc2 Tyr15 (#9111), eIF4E Ser209 (#9741), and ERK1/2 Thr202/Tyr204 (#4370) were obtained from Cell Signaling Technology (Beverly, MA, USA). RKIP (#37-2100) was obtained from Invitrogen. p-Cdk2 Thr14/Tyr15 (sc-28435-R), ERK1/2 (sc-94), and p27 (sc-528) were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Anti-mouse CD31 (#2502) antibody was purchased from BioLegend (San Diego, CA, USA).

Huynh H., Ng W.H, & Soo K.C. (2023). Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 25(1), 17.

+ Open protocol

+ Expand

Antibody Panel for Cancer Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies against AKT (#9272), FGFR-3 (#4574), FGFR-4 (#8562), p70S6K (#9202), Survivin (#2803), Cdk2 (#2546), Cdc25C (#4688), Cyclin B1 (#4138), cleaved caspase 3 (#9661), cleaved PARP (#5625), Cdc2 (#9112), Rb (#9313), S6R (#2217), 4EBP1 (#9452) and α-tubulin (#2144) were obtained from Cell Signaling Technology, Beverly, MA, USA. Phosphorylation-specific antibodies against AKT Ser473 (#9271), FRS2-α Tyr439 (#3861), p70S6K Thr421/424 (#9204), S6R Ser235./236 (#2211), 4EBP1 Thr70 (#9455), Histone 3 Ser10 (#9701), Cdc2 Tyr15 (#9111), p-mTOR (#2971), p-Rb (#9308) and ERK1/2 Thr202/Tyr204 (#4370) were also obtained from Cell Signaling Technology, Beverly, MA, USA. The antibodies against FGFR-2 (sc-122), ERK1/2 (sc-94), FRS2-α (sc-17841), E2F1 (sc-251) and p27 (sc-528) were obtained from Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA. The antibody LYVE-1 (AB-2988) was obtained from EMD Millipore, Billerica, MA, USA. The anti-mouse CD31 (#2502) antibody was obtained from BioLegend, San Diego, CA, USA. Infigratinib and Sorafenib were purchased from Selleck Chemicals, Houston, TX, USA. Bevacizumab (Avastin) was from Genentech, Inc., South San Francisco, CA, USA.

Le T.B., Vu T.C., Ho R.Z., Prawira A., Wang L., Goh B.C, & Huynh H. (2020). Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 21(24), 9405.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!